Translating Biochemical Potency Into Cellular Target Inhibition

Why Potency Changes Between an Enzyme Assay and a Cell

A biochemical IC50 is not a universal property of a compound. It is the concentration that produces 50% inhibition under a particular assay’s conditions, including its substrate concentration, enzyme concentration, incubation time, and definition of inhibitor concentration. A cell presents different conditions: substrate and ATP concentrations may differ, drug may not cross the membrane efficiently, and binding to cellular components can reduce the unbound concentration available to the target.

The practical task is to separate these influences rather than treat the biochemical IC50 as the cellular target-inhibition constant. The earlier material on competitive inhibition establishes how substrate concentration changes apparent potency; here the emphasis is on translating between assay and cellular contexts. The resulting calculation is a mechanistic expectation, not a guarantee that a measured cellular response will match it.

Definition: The IC50 is the inhibitor concentration producing 50% inhibition under stated experimental conditions. For a reversible inhibitor, \(K_i\) is an inhibition constant describing inhibitor binding in the specified mechanism. IC50 and \(K_i\) are not interchangeable: IC50 depends on assay conditions, whereas \(K_i\) is a mechanistic parameter under the model used to estimate it.

Substrate Conditions Set Biochemical IC50

For a reversible competitive inhibitor at equilibrium, assume the inhibitor and substrate compete for the same enzyme state, the assay measures initial rate, substrate concentration is fixed, and inhibitor is not substantially depleted by binding to enzyme. Under Michaelis–Menten conditions, the rate without inhibitor is \(v_0=V_{\max}[S]/(K_m+[S])\). With inhibitor concentration \([I]\), the competitive model gives \(v=V_{\max}[S]/(K_m(1+[I]/K_i)+[S])\).

At the IC50, the inhibited rate is half the uninhibited rate. Dividing the two rate expressions and setting \(v/v_0=1/2\) gives:

\frac{v}{v_0} =\frac{K_m+[S]}{K_m(1+[I]/K_i)+[S]} =\frac{1}{2} \quad\Longrightarrow\quad IC_{50}=K_i\left(1+\frac{[S]}{K_m}\right).

This is the Cheng–Prusoff relationship for this competitive-inhibition setting. It shows why the same inhibitor can have different biochemical IC50 values at different substrate concentrations. When \([S]\) is much smaller than \(K_m\), IC50 approaches \(K_i\); as \([S]\) increases, more inhibitor is needed to halve the rate. The relationship does not apply unchanged to noncompetitive, mixed, irreversible, or time-dependent inhibition.

Worked Example: Changing Substrate Concentration

Suppose a hypothetical reversible competitive inhibitor has \(K_i=0.0500\ \mu\text{M}\) for an enzyme with \(K_m=20.0\ \mu\text{M}\). Calculate its biochemical IC50 at substrate concentrations of \(10.0\ \mu\text{M}\) and \(90.0\ \mu\text{M}\), assuming the model conditions above hold.

At \(10.0\ \mu\text{M}\) substrate:

IC_{50}=0.0500\left(1+\frac{10.0}{20.0}\right) =0.0500(1.50) =0.0750\ \mu\text{M}.

At \(90.0\ \mu\text{M}\) substrate:

IC_{50}=0.0500\left(1+\frac{90.0}{20.0}\right) =0.0500(5.50) =0.275\ \mu\text{M}.

The predicted IC50 is higher at the higher substrate concentration, even though the inhibitor’s \(K_i\) is unchanged. Thus, comparing IC50 values across assays without checking substrate conditions can make an unchanged inhibitor-target interaction look weaker or stronger.

ATP Competition in Cells

For an ATP-competitive inhibitor of a kinase, ATP plays the role of the competing substrate in the simple model. If ATP is the relevant competing ligand and the assumptions of reversible competition apply, the apparent intracellular concentration for half inhibition is:

IC_{50,\mathrm{cell},u} =K_i\left(1+\frac{[ATP]_{\mathrm{cell}}}{K_{m,ATP}}\right).

Here the subscript \(u\) denotes an unbound inhibitor concentration at the target. This expression is a useful first approximation, not a claim that every kinase assay or cell obeys a single-substrate Michaelis–Menten model. Cellular ATP can be much higher than ATP in a biochemical assay, so an inhibitor may appear potent in vitro yet require a higher unbound concentration in cells. The shift depends on both ATP concentration and the target’s \(K_{m,ATP}\), not ATP concentration alone.

Worked Example: Estimating an ATP-Competition Shift

Consider a hypothetical ATP-competitive inhibitor with \(K_i=0.0200\ \mu\text{M}\). Let \(K_{m,ATP}=0.500\ \text{mM}\), ATP in the biochemical assay be \(0.100\ \text{mM}\), and cellular ATP be \(5.00\ \text{mM}\). Assume the same target mechanism applies in both settings.

In the biochemical assay:

IC_{50,\mathrm{assay},u} =0.0200\left(1+\frac{0.100}{0.500}\right) =0.0200(1.20) =0.0240\ \mu\text{M}.

In the cell:

IC_{50,\mathrm{cell},u} =0.0200\left(1+\frac{5.00}{0.500}\right) =0.0200(11.0) =0.220\ \mu\text{M}.

The model predicts a cellular unbound IC50 about \(0.220/0.0240=9.17\) times the assay unbound IC50. This difference follows from ATP competition alone; it does not yet account for whether the drug reaches the intracellular target.

From Medium Concentration to Unbound Drug at the Target

A nominal concentration added to cell-culture medium is not necessarily the concentration available to enter cells. Some drug can bind to proteins or other medium components. After crossing the membrane, drug can also bind nonspecifically to cellular constituents or be sequestered away from the target. These effects are distinct from ATP competition: competition sets the concentration needed at the target, while binding and access determine how much of the administered concentration reaches that target.

Definition: Let \(C_{\mathrm{medium,nom}}\) be the nominal concentration added to the medium, and let \(f_{u,\mathrm{medium}}\) be the unbound fraction in that medium. Define \(K_{p,uu}\) as the ratio of unbound intracellular concentration to unbound medium concentration at the relevant time. Under this definition, \(C_{u,\mathrm{cell}}=K_{p,uu}f_{u,\mathrm{medium}}C_{\mathrm{medium,nom}}\). This translation assumes the measured concentrations represent the relevant exposure and that the ratio is applicable over the range considered.

For the simple competitive model, fractional target inhibition is \(C_{u,\mathrm{cell}}/(C_{u,\mathrm{cell}}+IC_{50,\mathrm{cell},u})\). Combining this with the concentration relationship gives a nominal medium IC50. This calculation assumes equilibrium or an appropriate matched exposure time, a stable \(K_{p,uu}\), no substantial target depletion, and no additional mechanism altering target activity.

\text{Target inhibition} =\frac{C_{u,\mathrm{cell}}}{C_{u,\mathrm{cell}}+K_i(1+[ATP]_{\mathrm{cell}}/K_{m,ATP})}, \qquad IC_{50,\mathrm{medium,nom}} =\frac{K_i(1+[ATP]_{\mathrm{cell}}/K_{m,ATP})} {K_{p,uu}f_{u,\mathrm{medium}}}.

Worked Example: Combining ATP Competition and Cellular Access

A hypothetical inhibitor has \(K_i=0.0300\ \mu\text{M}\), \(K_{m,ATP}=1.00\ \text{mM}\), and cellular ATP \(=5.00\ \text{mM}\). Assume \(K_{p,uu}=0.0500\) and \(f_{u,\mathrm{medium}}=0.800\). Estimate target inhibition at a nominal medium concentration of \(1.00\ \mu\text{M}\), then calculate the nominal medium concentration predicted to produce 50% target inhibition.

First calculate the cellular unbound IC50:

IC_{50,\mathrm{cell},u} =0.0300\left(1+\frac{5.00}{1.00}\right) =0.180\ \mu\text{M}.

At \(1.00\ \mu\text{M}\) nominal in the medium, the estimated unbound intracellular concentration is:

C_{u,\mathrm{cell}} =0.0500(0.800)(1.00) =0.0400\ \mu\text{M}.

The predicted inhibition is therefore:

\frac{0.0400}{0.0400+0.180} =0.182,

or about 18.2%. For 50% inhibition, the intracellular unbound concentration must equal \(0.180\ \mu\text{M}\). The corresponding nominal medium concentration is:

IC_{50,\mathrm{medium,nom}} =\frac{0.180}{0.0500(0.800)} =4.50\ \mu\text{M}.

The estimated cellular IC50 is far above the target-level unbound IC50 because both medium binding and limited intracellular access reduce the concentration reaching the target.

Diagnostics, Alternatives, and Limitations

A useful translation starts with the mechanism and the concentration basis of each reported value. Check whether the biochemical assay used an appropriate substrate concentration and whether the reported inhibitor concentration is nominal or corrected for nonspecific binding. For a cellular estimate, determine whether the compound is ATP-competitive, whether intracellular ATP and \(K_{m,ATP}\) are known or reasonably approximated, and whether intracellular access has been measured. A comparison is not interpretable if one value is unbound and the other is nominal.

Several observations can signal that the simple translation is failing:

Cellular potency changes with assay duration, suggesting slow equilibration, time-dependent inhibition, or changing intracellular exposure.
Inhibition does not track estimated unbound intracellular concentration across conditions, suggesting that \(K_{p,uu}\), mechanism, or target engagement may not be represented adequately.
Increasing substrate does not shift potency as predicted for competitive inhibition, raising the possibility of another inhibition mechanism or assay interference.
Apparent potency depends strongly on enzyme or target concentration, which can indicate tight binding and inhibitor depletion; the ordinary Cheng–Prusoff relationship may then be inadequate.
Cellular effects occur without corresponding target inhibition, or target inhibition occurs without the expected downstream effect. Such a mismatch can reflect biology beyond this target-level calculation and should not be resolved by changing the biochemical IC50 alone.

When assumptions are weak, alternatives include measuring free inhibitor in the assay, determining \(K_i\) under multiple substrate concentrations, measuring unbound intracellular exposure, or directly quantifying cellular target engagement. These approaches address different uncertainties; none automatically replaces the others. A direct cell-based potency measurement is valuable for describing activity in that assay, but by itself it may not identify whether the shift arose from ATP competition, access, binding, or another mechanism.

The model also has limits even when calculations are internally consistent. ATP may vary across cell types or metabolic states; the inhibitor may interact with more than one target state; substrate concentrations may be dynamic; and intracellular partitioning may not be at equilibrium. Moreover, target inhibition is not the same as a pathway biomarker response. The latter depends on additional system properties and requires a separate link from target activity to pathway output.

Common pitfall: “The compound has a biochemical IC50 of \(0.1\ \mu\text{M}\), so \(0.1\ \mu\text{M}\) in the medium should inhibit half the cellular target.” This treats an assay-specific value as a universal concentration and ignores substrate or ATP competition, free fraction, and cellular access. Instead, identify the assay conditions, estimate the unbound target-level concentration needed for inhibition, and translate it to the administered medium concentration only with an explicit access and binding model.

Check Your Understanding

Answer each question using the assumptions stated. Full solutions follow.

A competitive inhibitor has \(K_i=0.0400\ \mu\text{M}\), \(K_m=10.0\ \mu\text{M}\), and assay substrate concentration \(30.0\ \mu\text{M}\). What IC50 does the model predict?
For an ATP-competitive inhibitor, what happens to predicted cellular unbound IC50 if cellular ATP rises while \(K_i\) and \(K_{m,ATP}\) remain fixed?
A cellular estimate uses \(K_{p,uu}=0.250\), \(f_{u,\mathrm{medium}}=0.500\), and a target-level unbound IC50 of \(0.200\ \mu\text{M}\). What nominal medium IC50 is predicted?
Why is it not valid to compare a nominal biochemical IC50 directly with a cellular unbound IC50 without checking how each concentration was defined?

Solutions. (1) \(IC_{50}=0.0400(1+30.0/10.0)=0.160\ \mu\text{M}\). (2) It increases, because the factor \(1+[ATP]_{\mathrm{cell}}/K_{m,ATP}\) increases. (3) \(IC_{50,\mathrm{medium,nom}}=0.200/(0.250\times0.500)=1.60\ \mu\text{M}\). (4) The nominal concentration may include drug bound to assay components, whereas an unbound concentration does not; comparing them as if they represented the same exposure can create a spurious potency shift.